Targeting BCAP with new drugs could benefit people with inflammatory bowel disease

Reviewed by Emily Henderson, B.Sc.Nov 17 2020

Managing the activity of the BCAP protein could help the body repair intestinal tissue from damage caused by inflammation, according to a new study led by experts at Cincinnati Children's.

The findings, published online Nov. 16, 2020, in PNAS, suggest that targeting BCAP with new medications could benefit people living with conditions such as inflammatory bowel disease (IBD).

The multi-center research team was led by first author Ricardo Irizarry-Caro, BSc, and senior author Chandrashekhar Pasare, DVM, PhD, at Cincinnati Children's Division of Immunobiology,

This study provides fundamental understanding of how macrophages regulate their responses to pathogens to provide an effective yet controlled inflammatory response and avoid damage of the host tissue. More importantly, this study has implications for small-molecule drug discovery targeting BCAP, which could be used to either promote reparative macrophage transition or induce a robust inflammatory response by just altering one single protein."

Chandrashekhar Pasare, DVM, PhD, Study Senior Author, Division of Immunobiology, Cincinnati Children's Hospital Medical Center

Dampening inflammation would be helpful for managing inflammatory diseases such as IBD and rheumatoid arthritis. Meanwhile, in cancer treatment, promoting inflammation could help drive immune responses against solid tumors.

Macrophages and inflammation

When macrophages sense bacterial pathogens such as E.coli, they activate an inflammatory response to get rid of the pathogen. However, this response needs to be kept in check to avoid damaging host tissue.

The new study shows that macrophages employ a molecule called BCAP to transition into a reparative state following clearance of infection. Turning down macrophage-triggered immune response once their task is complete is important because uncontrolled inflammation can lead to diseases such as inflammatory bowel disease (IBD).

Macrophages utilize Toll-Like Receptors (TLRs) to sense various pathogens, and activation of these receptors leads to early inflammation. The authors found that downstream of TLR activation, BCAP simultaneously activates a parallel pathway called the PI3K-AKT pathway, which acts to limit these inflammatory signals.

Specifically, researchers found that BCAP downstream of TLR activation inhibited two key proteins, GSK3b and FOXO1, which places a cap on the inflammation triggered by pathogen sensing. Yet this cap was not enough by itself to make macrophages stand down.

The team also found that BCAP was necessary for promoting a metabolic process called 'histone lactylation,' which leads to macrophage transition and supports intestinal repair after injury.

The co-authors say future research will focus on finding or developing drugs capable of controlling BCAP activity to dampen inflammation and promote tissue repair.